Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $10.40 Consensus PT from Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $10.40.

IRWD has been the subject of a number of analyst reports. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Wells Fargo & Company dropped their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Leerink Partners started coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target for the company. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, Capital One Financial cut shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th.

Ironwood Pharmaceuticals Price Performance

IRWD opened at $4.11 on Tuesday. The company has a market capitalization of $656.53 million, a price-to-earnings ratio of -145.33 and a beta of 0.47. The business’s 50-day moving average price is $4.29 and its two-hundred day moving average price is $5.52. Ironwood Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company’s revenue was down 19.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 EPS. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its position in Ironwood Pharmaceuticals by 244.8% during the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock worth $6,775,000 after acquiring an additional 552,227 shares during the last quarter. Entropy Technologies LP bought a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at $693,000. First Eagle Investment Management LLC grew its holdings in Ironwood Pharmaceuticals by 10.5% in the 1st quarter. First Eagle Investment Management LLC now owns 1,002,225 shares of the biotechnology company’s stock valued at $8,729,000 after buying an additional 95,000 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Ironwood Pharmaceuticals by 339.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 195,057 shares of the biotechnology company’s stock worth $1,699,000 after buying an additional 150,663 shares during the period. Finally, Edgestream Partners L.P. acquired a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth $2,581,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.